TNFRSF1B and neoplasm: Tumour-specific immune cells (CD8+ T cells, CD8+ T cells plus TNFR2+CCR8+ Tregs, or CD8+ T cells plus TNFR2−CCR8− Tregs) or the phosphate-buffered saline (PBS) control was injected into the CDX model five days after tumour inoculation (Figure 4A).